PTO/SB/21 (09-06) Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENTOR PROPERTY OF COMMENTOR OF COMMENTO

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

09/903,665-Conf. #3102 Filing Date July 13, 2001 First Named Inventor Giancarlo Santus Art Unit 1614 **Examiner Name** Frederick F. Krass Attorney Docket Number 04266/1006895-US2

Total Number of Pages in This Submission ENCLOSURES (Check all that apply) After Allowance Communication Fee Transmittal Form Drawing(s) Appeal Communication to Board of x | Fee Attached Licensing-related Papers Appeals and Interferences Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information **Provisional Application** Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please X Other Endocated Identify below): Extension of Time Request **Terminal Disclaimer** 3 References attached **Express Abandonment Request** Request for Refund Return Receipt Postcard x | Information Disclosure Statement CD, Number of CD(s) Certified Copy of Priority Landscape Table on CD Document(s) Reply to Missing Parts/ Remarks Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name DARBY & DARBY P.C. Signature Printed name Irina E. Vainberd Reg. No. Date 48,008 December 6, 2006



pplication No. (if known): 09/903,665

Attorney Docket No.: 04266/1006895-US2

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. in an envelope addressed to:

MS Missing Parts Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on December 6, 2006

Date

Signature
Signature
Signature

Typed or printed name of person signing Certificate

N/A

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Supplemental Information Disclosure Statement (5 pages) IDS (Citation) by Applicant (9 References, 3 attached) (1 page)

Transmittal (1 page)
Fee Transmittal (1 page)

Check in the amount of \$180.00

12807

O & 2006 Undag Ne Paperwork	Reduction Act of 199	5, no person are required		ent and Trader tion of informa		PARTMENT C s a valid OMB	F COMN
	Tective on 12/08/2004		Anadia dia a N	- 1	<i>nplete if Know</i> 09/903,665-Co		
			7.00.000.00.000.00			JIII. #3 IUZ	
rec	FEE TRANSMITTAL			Filing Date July 13, 2001 First Named Inventor Giancarlo Sa		tue	
F	or FY 200	6	Examiner Nam		Frederick F. K		
Applicant claims	small entity status.	See 37 CFR 1 27			1614		
TOTAL AMOUNT OF		(\$) 180.00	Art Unit Attorney Dock	at No.	04266/100689	15-US2	
			Attorney Dock	51140.			
METHOD OF PAY							
	لبا		ш	r (please ider			
Deposit Account	Deposit Account Num	ber: <u>04-0100</u> Deposit	Account Name:		Darby & Darby	P.C.	
For the above-	identified deposit	account, the Directo	is hereby authori	zed to: (che	eck all that apply)		
Charge f	ee(s) indicated be	elow	Cha	rge fee(s) in	idicated below, e	xcept for th	e filin
	ny additional fee(nder 37 CFR 1.16	(s) or underpayments and 1.17	of x Cred	lit any overp	payments		
FEE CALCULATIO	N						
1. BASIC FILING, SEA	-						
	FILIN	IG FEES S Small Entity	EARCH FEES Small Entite		NATION FEES Small Entity		
Application Type	<u>Fee (\$)</u>	Fee (\$) Fee		Fee (\$)		Fees P	aid (\$)
Utility	300	150 50	0 250	200	100		
Design	200	100 10	0 50	130	65		
Plant	200	100 30	0 150	160	80		
Reissue	300	150 50	0 250	600	300		
Provisional	200	100	0 0	0	0		
2. EXCESS CLAIM FE	ES					Fee (\$)	Small E Fee
Fee Description Each claim over 20 (in	aludina Daissuas)				50	100
Each independent claim	•	•				200	10
Multiple dependent cla		ing recissoos)				360	13
		Fee (\$) Fe	Paid (\$)	N	lultiple Depende		-
- =	x	=	(*)			Fee Paid (\$)
HP = highest number of to	al claims paid for, if g	reater than 20.					_
Indep. Claims E	xtra Claims 1	Fee (\$) Fe	Paid (\$)				
HP = highest number of inc	dependent claims paid	d for, if greater than 3.	-	_			_
3. APPLICATION SIZE If the specification an listings under 37 C	FEE d drawings exceed CFR 1.52(e)), the		due is \$250 (\$125	for small e			<u> </u>
Total Sheets	Extra Sheets	Number of eacl	additional 50 or fr			Fee F	aid (\$
100	=	/50	(round up to a w	hole number)	x	=	
4. OTHER FEE(S)						<u>Fees</u>	Paid (
1 .		e (no small entity di 806 Submission of	-	Disclosure	Statement	18	0.00
						.0	• •

SUBMITTED BY				
Signature	Mkanf_	Registration No. (Attorney/Agent) 48,000	Telephone	(212) 527-7634
Name (Print/Type)	Irina E. Vainberg		Date	December 6, 2006



Docket No.: 04266/1006895-US2

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Giancarlo Santus et al.

Application No.: 09/903,665

Filed: July 13, 2001 Art Unit: 1614

For: THERAPEUTIC COMPOSITIONS FOR

INTRANASAL ADMINISTRATION WHICH

INCLUDE KETOROLAC

Examiner: Frederick F. Krass

Confirmation No.: 3102

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This Supplemental Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed: (Check one of the boxes A-D)

Application	No _. : 09/903,665	2	Docket No.: 04266/1006895-US2
☐A.		nonths of the enti	the above-identified national ry into the national stage of the
B.	before the mailing date of a action after filing a request for		n on the merits, or a first office mination.
x C.	• • • • • • • • • • • • • • • • • • • •	ecessary statemen	rejection or allowance, and nt in box "i" below or paid the
((check one of the boxes "i" and	d "ii" below:)	
[i. Counsel states that, information listed here	=	on and belief, each item of e of boxes (a) or (b))
	· · ·	gn application no	from a foreign patent office in the transfer more than three months prior
	counterpart foreig undersigned after	gn application making reasonab gnated in 1.56(c)	om a foreign patent office in a and, to the knowledge of ole inquiry, was not known to more than three months prior
	x ii. A check for the fee set is enclosed.	forth in 1. 17(p),	, presently believed to be \$180,
D.	petitions under 37 C.F.R. 1.9 37 CFR 1.17(i) a check in	97(d) for the conthe the amount of \$	nent of the issue fee: Applicant asideration of this IDS. Under \$180.00 is enclosed. Counsel ach item of information listed

(check one of the boxes "a" and "b" below:)

herein was

 (a) first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS. 	
2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO/SB/0 all patents, publications, or other information submitted for consideration by the office, e incorporated into this IDS or as an attachment hereto. A copy of each document listed is attacked except as explained below.	either
(check boxes A, B and/or C and fill in blanks, if appropriate.)	
A. Pursuant to the 37 C.F.R. § 1.98(a)(2)(ii), a copy/copies of the U.S. Patent(s) and/or U.S. Patent Application Publication(s) on PTO/SB08 is/are not being submitted.	
B. Document(s) is (are) deemed substantially cumulative to document(s), and, in accordance with 1.98(c), only a copy of each of the latter documents is enclosed.	
x C. Certain documents were previously cited by or submitted to the Office in the following prior applications, which are relied upon under 35 U.S.C. 120:	
Serial No. 07/875,700 filed 4/29/1992 Serial No. 08/383,707 filed 2/1/1995	
Applicant identifies these documents by attaching hereto copies of the forms PTO-892, PTO-and/or PTO/SB/08 from the files of the prior application(s) or a fresh PTO/SB/08 listing to documents, and request that they be considered and made of record in accordance with 1.98(d) 37 CFR 1.98(d), copies of these documents need not be filed in this application.	these
3. Cite No(s) are not in the English language. In accordance with 1.98(c), Applicant states:	

3

Docket No.: 04266/1006895-US2

Application No.: 09/903,665

	An English translation of each document (or of the pertinent portions thereof), or a copy of each corresponding English-language patent or application, or English-language abstract (or claim) is enclosed.
	The requirement for a concise explanation of the relevance of any foreign language document is satisfied by the attached search report; citation of the documents cited in the search report shall not be construed as an admission that they are or are considered to be, material to patentability of the subject matter claimed herein (See MPEP §609).
	A concise explanation of the relevance of document(s) is set forth as follows: [Insert concise explanation of relevance]
	A concise explanation of the relevance of document(s) can be found on page(s) of the specification.
	A concise explanation of document(s) can be found on the attached sheet.
	No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 in the preamble to the final rules; 1135 OG 13 at 20).
L	Other information being provided for the examiner's consideration follows:
[A/An prosecution ofapplication.]	Search Report, dated, which issued during theApplication No which corresponds to the present
6. In ac	ecordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be presentation that a search has been made or that information cited is, or is

6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless other-wise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Early and favorable consideration is earnestly solicited.

Docket No.: 04266/1006895-US2

Application No.: 09/903,665

Our check in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p) is enclosed. The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

5

Dated: December 6, 2006

Respectfully submitted,

Irina E. Vainberg

Registration No.: 48,008 DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO 09/903,665-Conf. #3102 Application Number INFORMATION DISCLOSURE Filing Date July 13, 2001 Giancarlo Santus STATEMENT BY APPLICANT First Named Inventor Art Unit 1614 (Use as many sheets as necessary) Not Yet Assigned Examiner Name 1 04266/1006895-US2 1 of Attorney Docket Number Sheet

	U.S. PATENT DOCUMENTS						
F		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where		
Examiner Initials*	ner Cite Publication Date		MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevan Figures Appear		
	AA*	US-4,919,939	04-24-1990	Baker			
	AB*	US-4,994,439	02-19-1991	Longenecker et al.			
	AC*	US-5,049,386	09-17-1991	Eppstein et al.			
	AD*	US-5,091,182	02-25-1992	Ong et al.			
	AE*	US-5,143,731	09-01-1992	Viegas et al.			
	AF*	US-5,855,907	01-05-1999	Peyman			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	ВА	WO-90/001322	02-20-1990	Hussain, et al.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issue the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	• 1 The magazine journal serial symposium catalog etc.) date pade(s), volume-issue number(s), publisher, city			
	CA	Rubin, M.D. et al Comparison Long-Term Safety of Ketorolac Tromethamine and Aspirin in the Treatment of Chronic Pain.Pharmacotherapy (1990) 10(6pt. 2) pg. 106S-110S		
	CB*	Santus, et al., Nasal Formulations of Ketorolac Tromethamine Technological Evaluation- Bioavailability and Tolerability in Rabbits, IL Farmaco, 48 (12), 1709-1723; 1993		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.